BNP Paribas Financial Markets Lowers Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

BNP Paribas Financial Markets cut its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 91.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,819 shares of the medical device company's stock after selling 268,768 shares during the quarter. BNP Paribas Financial Markets' holdings in Tandem Diabetes Care were worth $894,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TNDM. Hood River Capital Management LLC purchased a new stake in Tandem Diabetes Care during the fourth quarter worth about $46,035,000. Park West Asset Management LLC grew its holdings in shares of Tandem Diabetes Care by 49.5% in the 4th quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock worth $57,632,000 after acquiring an additional 530,000 shares during the period. Baillie Gifford & Co. increased its stake in Tandem Diabetes Care by 235.7% in the 4th quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company's stock valued at $26,875,000 after purchasing an additional 523,843 shares in the last quarter. ArrowMark Colorado Holdings LLC raised its holdings in Tandem Diabetes Care by 14.1% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock worth $98,108,000 after purchasing an additional 337,026 shares during the last quarter. Finally, GW&K Investment Management LLC boosted its position in Tandem Diabetes Care by 18.0% during the fourth quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock worth $76,488,000 after purchasing an additional 323,674 shares in the last quarter.

Tandem Diabetes Care Stock Performance

TNDM traded up $0.61 on Tuesday, hitting $21.33. 73,237 shares of the company's stock were exchanged, compared to its average volume of 1,481,734. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The stock has a fifty day moving average of $19.40 and a two-hundred day moving average of $27.35. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The firm has a market cap of $1.42 billion, a PE ratio of -11.04 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). The firm had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The firm's revenue was up 22.3% on a year-over-year basis. During the same period last year, the business earned ($0.65) EPS. On average, research analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on TNDM shares. Stifel Nicolaus lowered their price objective on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. The Goldman Sachs Group reduced their target price on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Citigroup boosted their price target on Tandem Diabetes Care from $20.00 to $24.00 and gave the stock a "neutral" rating in a report on Thursday, May 22nd. Mizuho began coverage on shares of Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a "neutral" rating and a $20.00 target price for the company. Finally, Robert W. Baird decreased their price target on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating on the stock in a research note on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of "Moderate Buy" and a consensus target price of $37.47.

Insider Activity at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business's stock in a transaction dated Friday, March 7th. The stock was acquired at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the acquisition, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.90% of the company's stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.